Extracorporeal Shockwave Therapy for the Treatment of Advanced Angina Pectoris
Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones.
The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with refractory angina not amenable to revascularization with angioplasty or bypass surgery.
|Refractory Angina Pectoris||Device: Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)||Phase 1|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Shockwave Treatment for Advanced Angina in Maastricht (SWAAM). A Pilot Study|
- Time to Angina [ Time Frame: 6 months ]Change in time to angina using the modified Bruce exercise test from baseline to the 6 months post baseline assessment
- Change in SPECT [ Time Frame: 6 months ]The change in perfusion in pharmacological induced stress SPECT test (at rest and at stress) from baseline to 6 months post baseline (17 segment model)
- Change in AP-CCS [ Time Frame: 6 months ]The AP-CCS stage at the 6 months post baseline.
- Total Exercise time [ Time Frame: 6 months ]The change in total exercise time (Exercise Tolerance Test- ETT) from baseline to 6 months post baseline.
- Number of Angina attacks (patient diary) [ Time Frame: 6 months ]The change in the number of angina attacks from baseline to 6 months post baseline. The number of attacks per week will be documented.
|Study Start Date:||January 2009|
|Study Completion Date:||June 2012|
|Primary Completion Date:||January 2012 (Final data collection date for primary outcome measure)|
Treatment group. Patients in this group receive actual shockwave therapy.
Device: Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
Energy Density - 0.09 mJ/mm2
Low intensity shockwaves (1/10 the ones used in Lithotripsy) are delivered to myocardial ischemic tissue. Shockwaves are created by a special generator and are focused using a shockwave applicator device. The treatment is guided by standard echocardiography equipment. The shockwaves are delivered in synchronization with Patient R-wave to avoid arrhythmias. The treatment is painless.
At first, the patient undergoes stress-SPECT testing to identify the ischemic areas. Following that, the same area is localized by the ultra-sound device and the shockwaves are focused to the ischemic area. Several treatment session (9 in total, spread over 9 weeks) are required for optimal results.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01219218
|Academisch Ziekenhuis Maastricht|
|Principal Investigator:||Prof. Johannes Waltenberger, MD, PhD||Academisch Ziekenhuis Maastricht|